This site is intended for Healthcare Professionals only.

Dr Reddy’s Laboratories (UK) recalls two batches of Lacidipine 4 mg film-coated tablets

Date:

Share post:

The Medicines and Healthcare products Regulatory Agency (MHRA) has asked the pharmacies and wholesalers to stop supplying and quarantine all remaining stock of Dr Reddy’s Laboratories (UK)’s Lacidipine 4 mg Film-Coated tablets.

The company has recalled two batches of Lacidipine 4 mg Film-Coated tablets as a precautionary measure due to the presence of an unknown solvent-like odour.

MHRA said: “The tablets are normally odourless. However, in the affected batches, a solvent-like odour is present when the individual blisters are opened. Additionally, some patient complaints have noted that the tablets have an unusual taste. The investigation to determine the root cause and to identify and quantify the odour is ongoing.

“The issue is confined to batches B2202043 and B2202044 only. Other batches of Lacidipine 4 mg Film-Coated tablets marketed by Dr Reddy’s Laboratories (UK) are not affected.”

“The recall is a precautionary measure whilst the company completes the investigation. There are no concerns with the medicine and its ability to control blood pressure. Any suspected defective medicine should be reported via the MHRA Yellow Card scheme.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

DHSC Plans to Allow Hub and Spoke Models Across Different Pharmacy Ownerships Soon

It has decided to proceed with the implementation of the two hub and spoke models that it consulted...

NHS Long Term Workforce Plan: 350 more medical school places allocated

The Office for Students (OfS) has targeted under-doctored areas in its allocation of the medical school places The government has...

Continuing royal legacy: RPS appoints King Charles as new patron

King Charles's patronage signals a new era of support for the RPS's mission to advance healthcare and patient-well...

Cipla, Glenmark recall products from US market due to manufacturing issues

Cipla USA is recalling 59,244 packs of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution   Two Indian pharmaceutical companies,...